VivoSeq
Other

Lung Transplant Recipient

1

Pipeline Programs↗

4

Active Trials↗

5

Companies Involved↗

Lung Transplant Recipient is an early-stage landscape with 1 program across 5 companies. The most active players are TFF Pharmaceuticals, Inc., Merck & Co., Novartis.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

47/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TFF Pharmaceuticals, Inc.

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalA

APT Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Anakinra

Swedish Orphan Biovitrum

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

21

clinical trials

Completed7 · 33%
Terminated6 · 29%
Recruiting3 · 14%
Withdrawn1 · 5%
Suspended1 · 5%
No longer available1 · 5%
Other2 · 10%

Clinical Trials

Trial Activity

21 trials

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients
Recruiting·VVanderbilt University Medical Center·Phase 1·NCT04469842·48 enrolled
CMV Immunity Monitoring in Lung Transplant Recipients
Recruiting·NNYU Langone Health·Phase 2·NCT05708755·50 enrolled
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06476132·234 enrolled
BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction
Not yet recruiting·NNorthwestern University·Phase 1·NCT07410312·20 enrolled
Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study
Completed·UUniversity of Pittsburgh·Phase 3·NCT00177710·48 enrolled
Longitudinal and Cross-sectional Analysis of Pulmonary Microbiota in Lung Transplant Recipients Infected With Nocardia
Completed·—·N/A·NCT06594133·68 enrolled
Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients
Completed·Novartis logoNovartis·Phase 3·NCT01404325·130 enrolled
Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.
Completed·MMaimónides Biomedical Research Institute of Córdoba·Phase 3·NCT03699254·150 enrolled
A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients
Completed·Roche logoRoche·Phase 3·NCT01014442·68 enrolled
Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
Completed·UUniversity of Maryland, Baltimore·Phase 1/2·NCT01650545·21 enrolled
Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients
Completed·TThe Cleveland Clinic·Phase 2/3·NCT00137748·50 enrolled
Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients
Suspended·UUniversity Health Network, Toronto·Phase 2·NCT01254708·4 enrolled
Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients
Terminated·UUniversity of Pittsburgh·Phase 3·NCT00235651·12 enrolled
An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant Recipients
Terminated·TTFF Pharmaceuticals, Inc.·Phase 2·NCT05501574·14 enrolled
HP 129Xe MRI for Evaluation of CLAD in Lung Transplant Recipients
Terminated·TThe Hospital for Sick Children·Phase 2·NCT05550662·6 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)